A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients

Roy F. Chemaly(The University of Texas MD Anderson Cancer Center), Michael Boeckh, Francisco M. Marty(Brigham and Women's Hospital), Patrick J. Stiff(Loyola University Medical Center), Hans H. Hirsch(University of Basel), Kathleen M. Mullane(Karolinska University Hospital), Sanjeet Dadwal(City Of Hope National Medical Center), Jason W. Chien(Gilead Sciences (United States)), Alpana Waghmare(University of Washington), Silvy Lachance(Hôpital Maisonneuve-Rosemont), Ajit P. Limaye(University of Washington), Galia Rahav(Sheba Medical Center), Sudhakar Pipavath, David Gossage, Anne Bergeron(Délégation Paris 7), Dong‐Gun Lee(Korea University), Danielle Porter(Gilead Sciences (United States)), Roberto L. Patron(Mayo Clinic Hospital), Catherine B. Small(Cornell University), Per Ljungman(Leiden University Medical Center), Yae‐Jean Kim, Élodie Blanchard(Centre Hospitalier Universitaire de Bordeaux), Ying Guo(Gilead Sciences (United States)), Robert Jordan(Gilead Sciences (United States)), Drew J. Winston(University of California, Los Angeles), Matt McKevitt(Gilead Sciences (United States)), Timothy R. Watkins(Gilead Sciences (United States)), Polina German(Gilead Sciences (United States)), Guang‐Shing Cheng(Fred Hutch Cancer Center), Tsila Zuckerman(Johannes Gutenberg University Mainz)
Clinical Infectious Diseases
December 3, 2019
Cited by 75


Related Papers